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A R T I C L E   I N F O S U M M A R Y 
Drug delivery to the eye has always been an interesting and challenging field in 
pharmaceutical formulation and drug design. The aim of this research was the 
formulation development of thin erodible films for potential delivery of lopidine to 
treat glaucoma. Films were prepared using hyaluronic acid (HA) and 
hydroxypropyl methylcellulose (HPMC) as polymers, together with glycerol (GLY) 
as plasticiser. Single layer films were prepared using each polymer individually, as 
well as in combination to obtain composite thin films. Various combinations and 
concentrations were optimised to reach the desired transparency, which were then 
characterised for their physico-chemical and mechanical properties. The following 
ratios were selected for drug loading: 2% HPMC, 1% HA, 1% composite (HPMC 1:1 
HA) and 2% composite (HPMC 1.5:0.5 HA) with all of them containing a ratio of 2:1 
polymer to plasticiser. 
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INTRODUCTION 
The estimated number of visually impaired people in 
the world is 285 million, which is 4% of the global 
population. The unique anatomy and complicated 
physiology of the eye and the importance of 
maintaining visual clarity makes the eye a challenging 
organ for drug delivery purposes (Patel et al., 2013). 
Conventional eye drops are not efficient because of 
their low bioavailability, with only 5% of the dose 
reaching the site of action within the eye due to 
splashes during blinking, nasal drainage, small 
absorptive surface, lipophilicity and low permeability 
of the corneal epithelium (Addo, 2016). Severe chronic 
eye conditions such as glaucoma require better drug 
delivery systems in order to deliver site-specific, 
controlled drug release with appropriate 
bioavailability. Therefore, erodible films are required 
to overcome these limitations of current dosage forms, 
to ensure controlled release as well as increasing 
retention time and hence bioavailability. 
MATERIALS AND METHODS 
Single layer films were prepared using HPMC:GLY 
and HA:GLY gels in 2:1 ratio of polymer to plasticiser. 
Composite films were then prepared from gels 
comprising HPMC:HA:GLY with the same ratio of 
total polymer to plasticiser. The hydration and 
gelation of the polymers was carried out at room 
temperature, and dried in a 40ºC oven over night. The 
films were optimised by characterising for their 
physico-chemical properties using the following tests: 
transparency, tensile strength, elastic modulus, 
swelling capacity, mucoadhesion, attenuated total 
reflectance Fourier transform infrared (ATR FT-IR), 
differential scanning calorimetry (DSC) 
thermogravimetric analysis (TGA) and scanning 
electron microscopy (SEM). The single polymer films 
from 1% HA, 2% HPMC gels, composite films from 
1% (HPMC 1:1 HA) and 2% (HPMC 1.5:0.5 HA) gels 
met the desired criteria for drug loading 
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RESULTS AND DISCUSSION 
Both single polymer and composite films were 
thoroughly transparent, with digital images of the 
transparent films taken against a white, black 
numbered ruler to illustrate film clarity (Figure 1). The 
transparency was further examined by UV 
transmission and showed greater than 90% light 
transmission. The single polymer (1% HA, 2% HPMC) 
and composite (1% HPMC 1:1 HA; 2% HPMC 1.5:0.5 
HA) films had the optimum physical and mechanical 
properties (Table 1) for ocular drug delivery. 
 
 
Fig. 1. Transparency of (a) 1% HA:GLY, (b) 2% HPMC:GLY and 
(c) 1% composite (HPMC 1:1 HA) 
 
The ATR-FTIR results showed possible crosslinking of 
the polymers in the composite films as new peaks 
appeared which were not present in the single HA or 
HPMC films. These peaks include 2994 cm-1, 2827 cm- 
1, 1288 cm-1, 1265 cm-1, 1240 cm-1, 1214 cm-1 and 743 
cm-1. Also, the 1645 cm-1 peak of HPMC did not 
appear in the composite films, which is also an 
indication of chemical interaction. The DSC and TGA 
results were consistent in terms of water content, 
melting point and material decomposition. The SEM 
result showed smooth continuous (non-porous) film 
surface with negligible number of polymer particles 
on the surface of the film in the composite films. This 
is shown by the representative image of the composite 
film at x50 magnification (figure 2a), as well as the 
image of the same film at x1800 magnification (figure 
2b). This could be due to aggregation of HPMC and 
HA particles during the hydration process which is 
even stronger if the polymers are crosslinking. 
 
Fig. 2. Representative SEM image of 1% composite (HPMC 1:1 
HA); (a) x50 magnification and (b) x1800 magnification showing 
the small aggregated particle on the film surface.  
 
Table 1. Tensile strength, elastic modulus, mucoadhesion and swelling results for all the films formulated  
Gels for films 
(% w/v) 
Tensile strength (N/mm2) Elastic modulus (mPa) Peak adhesive 
force (N) 
Swelling capacity (%) 
0.5 % HPMC 11.2 19.6 1.9 965.3 
1.0% HPMC 25.4 7.7 1.6 360.3 
1.5% HPMC 40.9 8.8 1.4 570.7 
2.0% HPMC 32.5 9.9 2.1 715.2 
1.0% HA 10.1 0.9 2.2 1633.3 
1.5% HA 3.7 0.1 2.9 1463.9 
1% Composite 14.2 3.5 6.0 931.7 
2% Composite 45.7 14.8 3.7 804.3 
CONCLUSIONS 
Plasticised HA, HPMC and composite films of both 
polymers possessed ideal physico-chemical 
properties suitable for ocular delivery. The films 
containing single polymers, as well as the composite 
formulation of the two polymers formed transparent, 
flexible films which can be used for drug loading and 
thus as potential ocular drug delivery systems. Based 
on the analytical characterization, the 2% HPMC, 1% 
HA, 1% composite (HPMC 1:1 HA) and 2% composite 
(HPMC 1.5:.05 HA) have the required physico-
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